Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Additional data in pregnant adults who are Virologically suppressed reinforce safety and tolerability profile of Biktarvy in broad range of people with HIV
Sales reflect continued strong growth in oncology and vaccines
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
The company plans to add 1700 beds by FY27 through the organic route
Subscribe To Our Newsletter & Stay Updated
